The compound's headline result — explained with actual trial data. What ~15% visceral fat reduction means, why the mechanism preferentially targets VAT, and what happens after you stop.
Research context only. This article summarizes published clinical data for educational purposes. Not medical advice.
Not all body fat is equal. The fat you can see and pinch — subcutaneous fat — is largely cosmetic. The fat you can't see, wrapped around your liver, pancreas, and intestines deep in the abdominal cavity, is a different story. That's visceral fat, and it's metabolically active in ways that subcutaneous fat is not.
Visceral fat secretes inflammatory cytokines, disrupts insulin signaling, elevates triglycerides, and is strongly linked to cardiovascular disease, type 2 diabetes, metabolic syndrome, and all-cause mortality. Waist circumference is a rough proxy — but only imaging (CT or MRI) can accurately measure visceral adipose tissue (VAT).
The problem with most interventions: Diet and exercise reduce overall body fat, but they don't specifically target visceral fat. GLP-1 drugs like semaglutide and tirzepatide produce significant total fat loss, but VAT reduction is proportional rather than preferential. Tesamorelin's mechanism appears to preferentially mobilize visceral fat specifically — which is why it was developed for lipodystrophy, a condition of disproportionate visceral fat accumulation.
The two pivotal trials (LIPO-010 and LIPO-011) that earned tesamorelin its FDA approval are the gold standard evidence for its visceral fat effects. Both were randomized, double-blind, placebo-controlled trials — the highest standard of clinical evidence.
| Measurement | Tesamorelin | Placebo | Difference |
|---|---|---|---|
| VAT area change (cm²) | −26 to −37 cm² | +8 to +12 cm² | ~40–50 cm² in favor |
| VAT % change | ~−15% | ~+5% | ~20 percentage points |
| Waist circumference | Significant reduction | No change | Clinically meaningful |
| Trunk fat mass | Decreased | No change | Significant |
| Lean mass | No significant change | No significant change | Preserved in both groups |
| Subcutaneous fat | Minimal change | Minimal change | Not the primary target |
The subcutaneous fat finding is notable: while visceral fat decreased significantly, subcutaneous fat was largely unaffected. This confirms the preferential visceral targeting that makes tesamorelin mechanistically distinct from broad fat-loss interventions.
Visceral fat cells (adipocytes) have a higher density of GH receptors and are more responsive to GH-stimulated lipolysis than subcutaneous adipocytes. When tesamorelin elevates GH and downstream IGF-1, visceral fat is disproportionately mobilized because it's more biochemically responsive to the GH signal.
Additionally, visceral fat has higher lipolytic activity at baseline — it turns over faster. The GH stimulus from tesamorelin amplifies this existing metabolic activity preferentially in visceral depots.
The clinical implication: This makes tesamorelin particularly interesting as a complement to GLP-1 drugs. GLP-1 agents produce broad fat loss through caloric restriction mechanisms. Tesamorelin may add targeted visceral fat reduction on top — which is the rationale behind the Recomp Stack combining retatrutide with tesamorelin.
Visceral fat reduction has downstream metabolic consequences. The FDA trials tracked several secondary markers:
| Marker | Direction | Clinical Significance |
|---|---|---|
| Triglycerides | Modest decrease | Visceral fat drives hepatic triglyceride production; reduction expected |
| Total cholesterol | Minimal change | Not a primary mechanism |
| HDL cholesterol | Slight increase in some studies | Consistent with improved metabolic health |
| IGF-1 | ~100–150% increase | Primary GH-axis biomarker; confirms mechanism is working |
| Blood glucose / HbA1c | Slight elevation risk | GH can cause insulin resistance; monitor in at-risk patients |
| Lean mass | Preserved or slight increase | GH's anabolic signaling protects muscle during fat loss |
The 52-week extension phase of the FDA trials provided important data on what happens after discontinuation. Participants who stopped tesamorelin after 26 weeks showed progressive return of visceral fat toward baseline over the subsequent 26 weeks. Those who continued treatment maintained their VAT reduction.
This is consistent with how GH-axis interventions work — they manage an ongoing physiological condition rather than permanently resetting fat distribution. The practical implication is that long-term maintenance dosing or repeat cycles are likely necessary to sustain results.
For researchers: This rebound pattern doesn't diminish the compound's value — it contextualizes it. Managing expectations about duration of effect is important. The same rebound pattern is seen with GLP-1 drugs, and it doesn't stop millions of people from finding those compounds clinically valuable.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Tesamorelin 101 →